|
Share your experience: submit a drug review
Below are Fosamax Plus D (Alendronate / Cholecalciferol) reviews, ratings, comments submitted by patients and caregivers. Based on a total of 1 ratings/reviews, Fosamax Plus D has an overall score of 10. The effectiveness score is 10 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst. This information is not vetted and should not be cosidered as clinical evidence. | | Fosamax Plus D review by 60 year old female patient | | | Rating |
| Overall rating: | |  |
| Effectiveness: | | Highly Effective |
| Side effects: | | No Side Effects | | |
Treatment Info |
| Condition / reason: | | osteoporosis |
| Dosage & duration: | | 70mg/2800IU taken 1 weekly for the period of 2 years |
| Other conditions: | | none |
| Other drugs taken: | | none | | |
Reported Results |
| Benefits: | | Between 1998 and 2006, when I was going through menopause, my bone density went from normal to borderline osteoporosis, as shown by the results of two bone density tests given on those dates. After I received my bone density results in 2006, my physician put me on Fosamax, which I have taken regularly for the past two years. When I took a bone density test recently in 2008, my bone mineral density had increased by almost 6% over a two-year period. I remain in the range of osteopenia, but am midway now between normal and osteoporosis in my T-scores. |
| Side effects: | | I have experienced no adverse side effects at all while taking this medication. |
| Comments: | | I take a pill in the morning when I get up, once a week, on the same day each week. I take it with an 8 ounce glass of water and do not lay down, eat, or drink anything for at least 30 minutes. I also take calcium/d vitamin supplements daily, eat plenty of dairy products, walk at least 3 times a week, and avoid alcohol and soft drinks. I was already following these dietary habits when my previous bone density tests were done. Because of that, I credit fosamax with the improvement that has taken place. |
| |
|
